Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/19.CcrFU5Zy.js ...

According to research presented at the EAHAD 2024 Annual Congress, a new classification system enhances diagnosis and ...

A Lincoln nurse who specialises in looking after patients with blood disorders has been named Nurse of the Year. Alison ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 14 February 2025, approved efanesoctocog alfa (brand name Altuvoct) to be ...

The study shows that 94% of patients eliminated factor IX prophylaxis and maintained near-normal factor IX levels through ...

Four years after receiving Hemgenix in a Phase 3 trial, bleeding rates and the use of replacement therapy are low for men ...

CSL Behring has shared positive four-year results from a late-stage study of its haemophilia B gene therapy Hemgenix ...

CSL has received approval from the EC for Andembry (garadacimab) to prevent recurrent attacks of HAE in patients aged 12 ...

According to research presented at the EAHAD 2024 Annual Congress, spinal stenosis is emerging as a complication for aging hemophilia patients.

Novo Nordisk has shared positive results from a late-stage study of its investigational haemophilia A therapy Mim8 in ...